Nicotine Exposure in Pregnancy Affects Adult Sleep Patterns: Study

Aug.29.2022
Nicotine Exposure in Pregnancy Affects Adult Sleep Patterns: Study
Prenatal nicotine exposure affects sleep patterns in adult mice, according to a study published in Scientific Reports.

The study, titled "Persistent Sleep Alterations and Decreased Hippocampal Corticosteroid Receptor Expression in Adult Mice after Early Nicotine or Tizanidine Exposure," was published in Scientific Reports. Its goal was to determine the effects of prenatal exposure to nicotine and its byproducts on adults.


A research team used regular secondhand smoke concentrations to expose pregnant mice to nicotine and found that these same mice had a significant decrease in sleep during the transition between rest and activity phases in adulthood.


Giovanna Zoccoli, a professor of biomedical and neuro-motor science at the University of Bologna in Italy, said: "The results of this study show that adult sleep may be influenced by early-life events. According to our data, controlling environmental factors during pregnancy is not only important for women's health, but also crucial for their offspring.


The study also found that this prenatal exposure to smoke altered the expression and balance of hippocampal cortical steroid receptors. Zoccoli added, "Our data show that changes in sleep and relaxation regulation of cortical steroids in the hippocampus are concurrent." "These findings suggest that nicotine consumption during pregnancy is a stressor that can affect the hippocampal development of offspring and the sleep patterns of adult offspring.


Is there a detrimental impact of electronic cigarettes on the heart?


A recent study exposed mouse heart cells to vapor from a culture dish, concluding that e-cigarettes have a damaging effect on the heart. Award-winning science writer, bestselling author, and chairman of the American Council on Science and Health, Hank Campbell, explained why these findings are flawed.


A study report titled "In vitro and in vivo cardiac toxicity of a flavoring electronic nicotine delivery system" found that inhaling vanillin in mice increased sympathetic dominance in heart rate variability measurements. However, a new paper claims that using e-cigarettes instead of traditional cigarettes puts people's hearts at risk, but their study did not show this. Instead, they mixed chemicals in a petri dish with heart cells and used mice. Both are good exploratory experiments, but scientifically, they are invalid in supporting the conclusions drawn by the authors in the press release, according to Campbell.


In addition, Campbell explained that in the study, HL-1 cells from mice and later human cells produced in the laboratory were submerged in certain chemicals, but these so-called chemicals found in e-cigarettes are ones that humans have not been exposed to in the last 40,000 years.


Statement


This article is compiled based on information from a third-party source, and is intended for industry-related communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the truthfulness or accuracy of the article's contents. The translation of this article is solely for the purpose of industry exchange and research.


Due to limited translation ability, the compiled article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and international issues and positions.


The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us to have it removed.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FTC Scrutinizes Fifty Bar’s “Made in America” Claims as Vape Marketing Faces New Compliance Risk
FTC Scrutinizes Fifty Bar’s “Made in America” Claims as Vape Marketing Faces New Compliance Risk
The Federal Trade Commission sent a warning letter to Lucky Bar Holdings LLC over “Made in the USA” claims tied to Fifty Bar vape products, saying staff had reason to believe the products may be imported in whole or in significant part despite unqualified U.S.-origin marketing claims.
Jul.20
Senate Democrat Wyden Probes Trump Administration Vape Policy Shift, Seeks Records From HHS and Reynolds American
Senate Democrat Wyden Probes Trump Administration Vape Policy Shift, Seeks Records From HHS and Reynolds American
U.S. Senator Ron Wyden, the Democratic ranking member of the Senate Finance Committee, has launched an investigation into flavored vape policy changes and requested records from the Department of Health and Human Services (HHS), Reynolds American and Botanic Tonics. The investigation focuses on a timeline involving Reynolds American’s $5 million donation to MAGA Inc. in April 2026 and subsequent vape policy developments. Wyden said the review aims to examine potential links between political donations, corporate communications and government decisions. The investigation does not represent a finding of wrongdoing.
Innovation
Aug.07 by 2Firsts Perspectives
Product | KT&G Brings LOOP Nicotine Pouches to South Africa, Supporting ASF’s Expansion Across Africa
Product | KT&G Brings LOOP Nicotine Pouches to South Africa, Supporting ASF’s Expansion Across Africa
KT&G has introduced nicotine pouch brand LOOP in South Africa, expanding its modern oral nicotine portfolio. Developed by Swedish company Another Snus Factory (ASF), LOOP is a tobacco-free nicotine pouch brand. KT&G and U.S. tobacco company Altria previously participated in ASF’s strategic development, and the South Africa launch represents a further step in LOOP’s international expansion.
Aug.06
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
Product | PMI Launches Airport-Exclusive IQOS Skylens Limited Edition, Expanding From Japan’s Narita to Travel Retail Markets in 13 Countries Summary
Product | PMI Launches Airport-Exclusive IQOS Skylens Limited Edition, Expanding From Japan’s Narita to Travel Retail Markets in 13 Countries Summary
Philip Morris International (PMI) has introduced the airport-exclusive limited-edition IQOS ILUMA i PRIME Skylens, the company’s first device created specifically for airport travel retail. Inspired by the world of flight and finished in metallic blue, Skylens debuted at Narita International Airport in Japan before expanding into selected airport duty-free and travel-retail channels across 13 countries in Europe, Asia, the Middle East and Africa. The product retains the existing IQOS ILUMA i PRIME platform, with differentiation centered on airport exclusivity, design and travel-retail execution rather than a new heating architecture.
PMI
Aug.19
EU Tobacco Rules Face Pushback as Analysis Says 90% of Consultation Responses Raised Objections
EU Tobacco Rules Face Pushback as Analysis Says 90% of Consultation Responses Raised Objections
An analysis by We Are Innovation says more than 90% of over 82,000 responses to the European Commission’s public consultation on the Tobacco Products Directive revision raised at least one substantial objection to the proposed regulatory direction.
Jul.13